These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 32007639)
41. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R; Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417 [TBL] [Abstract][Full Text] [Related]
42. Transplant Outcomes in Beta-Thalassemia Major Patients Receiving Combined Granulocyte Colony-Stimulating Factor-Primed Bone Marrow and Cord Blood Graft Compared to Granulocyte Colony-Stimulating Factor-Primed Bone Marrow Alone. Wen J; Haque Q; Pei F; Chen L; Ruan Y; Liu X; He Y; Feng X; Li C; Wu X Acta Haematol; 2018; 140(1):20-29. PubMed ID: 30071526 [TBL] [Abstract][Full Text] [Related]
43. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Iannone R; Casella JF; Fuchs EJ; Chen AR; Jones RJ; Woolfrey A; Amylon M; Sullivan KM; Storb RF; Walters MC Biol Blood Marrow Transplant; 2003 Aug; 9(8):519-28. PubMed ID: 12931121 [TBL] [Abstract][Full Text] [Related]
44. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980 [TBL] [Abstract][Full Text] [Related]
45. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases]. Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474 [TBL] [Abstract][Full Text] [Related]
46. HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease. Pawlowska AB; Cheng JC; Karras NA; Sun W; Wang LD; Bell AD; Gutierrez L; Rosenthal J Biol Blood Marrow Transplant; 2018 Jan; 24(1):185-189. PubMed ID: 28939451 [TBL] [Abstract][Full Text] [Related]
47. G-CSF-Mobilized Blood and Bone Marrow Grafts as the Source of Stem Cells for HLA-Identical Sibling Transplantation in Patients with Thalassemia Major. Li Q; Luo J; Zhang Z; Liu L; Luo L; Yang G; Liu R; Shi L; Huang R; Wu M; Lai Y Biol Blood Marrow Transplant; 2019 Oct; 25(10):2040-2044. PubMed ID: 31207293 [TBL] [Abstract][Full Text] [Related]
48. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371 [TBL] [Abstract][Full Text] [Related]
49. Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation. Umeda K; Adachi S; Tanaka S; Ogawa A; Hatakeyama N; Kudo K; Sakata N; Igarashi S; Ohshima K; Hyakuna N; Chin M; Goto H; Takahashi Y; Azuma E; Koh K; Sawada A; Kato K; Inoue M; Atsuta Y; Takami A; Murata M; Pediatr Blood Cancer; 2015 Feb; 62(2):291-298. PubMed ID: 25307105 [TBL] [Abstract][Full Text] [Related]
50. Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin. Park BK; Kim HS; Kim S; Lee JW; Park YS; Jang PS; Chung NG; Jeong DC; Cho B Blood Res; 2018 Jun; 53(2):145-151. PubMed ID: 29963521 [TBL] [Abstract][Full Text] [Related]
51. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340 [TBL] [Abstract][Full Text] [Related]
52. Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis. Bleyzac N; Cuzzubbo D; Rénard C; Garnier N; Dubois V; Domenech C; Goutagny MP; Plesa A; Grardel N; Goutelle S; Janoly-Duménil A; Bertrand Y Bone Marrow Transplant; 2016 May; 51(5):698-704. PubMed ID: 26808568 [TBL] [Abstract][Full Text] [Related]
53. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395 [TBL] [Abstract][Full Text] [Related]
54. Alternative Donor/Unrelated Donor Transplants for the β-Thalassemia and Sickle Cell Disease. Fitzhugh CD; Abraham A; Hsieh MM Adv Exp Med Biol; 2017; 1013():123-153. PubMed ID: 29127679 [TBL] [Abstract][Full Text] [Related]
55. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; Mackinnon S Blood; 2000 Oct; 96(7):2419-25. PubMed ID: 11001893 [TBL] [Abstract][Full Text] [Related]
56. Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease. Foell J; Kleinschmidt K; Jakob M; Troeger A; Corbacioglu S Hematol Oncol Stem Cell Ther; 2020 Jun; 13(2):98-105. PubMed ID: 32202248 [TBL] [Abstract][Full Text] [Related]
57. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation]. Liu QF; Sun J; Zhang Y; Xu D; Liu XL; Xu B; Meng FY; Zhou SY Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172 [TBL] [Abstract][Full Text] [Related]
58. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Mielcarek M; Martin PJ; Leisenring W; Flowers ME; Maloney DG; Sandmaier BM; Maris MB; Storb R Blood; 2003 Jul; 102(2):756-62. PubMed ID: 12663454 [TBL] [Abstract][Full Text] [Related]
59. Allogeneic peripheral blood stem cell transplantation in children with homozygous beta-thalassemia and severe beta-thalassemia/hemoglobin E disease. Pakakasama S; Hongeng S; Chaisiripoomkere W; Chuansumrit A; Sirachainun N; Jootar S J Pediatr Hematol Oncol; 2004 Apr; 26(4):248-52. PubMed ID: 15087953 [TBL] [Abstract][Full Text] [Related]
60. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation. Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]